These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 21885000)

  • 1. Treatment of patients excluded from Eastern Cooperative Oncology Group 4599 and AVAiL studies: focus on brain metastasis and squamous histology.
    Morgensztern D; Govindan R
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S57-61. PubMed ID: 21885000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ongoing trials with bevacizumab and other antiangiogenic agents in lung cancer.
    Dowlati A
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S71-5. PubMed ID: 21885002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing the dose and schedule of anti-vascular endothelial growth factor antibodies in non-small-cell lung cancer.
    Klamerus JF; Brahmer JR
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S51-6. PubMed ID: 21884999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599.
    Somer RA; Sherman E; Langer CJ
    Clin Lung Cancer; 2008 Mar; 9(2):102-5. PubMed ID: 18501096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging safety data for bevacizumab in advanced non-small-cell lung cancer.
    Hirsh V
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S62-70. PubMed ID: 21885001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
    Cohen MH; Gootenberg J; Keegan P; Pazdur R
    Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer.
    Sandler AB; Johnson DH; Herbst RS
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4258s-4262s. PubMed ID: 15217970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab in non small cell lung cancer.
    Sandler A
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4613-6. PubMed ID: 17671151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Langer CJ; Natale RB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenesis inhibition in the treatment of lung cancer.
    Vokes E; Herbst R; Sandler A
    Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
    Sandler A; Gray R; Perry MC; Brahmer J; Schiller JH; Dowlati A; Lilenbaum R; Johnson DH
    N Engl J Med; 2006 Dec; 355(24):2542-50. PubMed ID: 17167137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.
    Socinski MA; Langer CJ; Huang JE; Kolb MM; Compton P; Wang L; Akerley W
    J Clin Oncol; 2009 Nov; 27(31):5255-61. PubMed ID: 19738122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
    de Gramont A; Van Cutsem E
    Oncology; 2005; 69 Suppl 3():46-56. PubMed ID: 16301835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC.
    Dansin E; Cinieri S; Garrido P; Griesinger F; Isla D; Koehler M; Kohlhaeufl M
    Lung Cancer; 2012 Jun; 76(3):373-9. PubMed ID: 22236866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer.
    Spigel DR; Anthony Greco F; Waterhouse DM; Shipley DL; Zubkus JD; Bury MJ; Webb CD; Hart LL; Gian VG; Infante JR; Burris HA; Hainsworth JD
    Lung Cancer; 2012 Oct; 78(1):70-5. PubMed ID: 22947511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach.
    Tassinari D; Sartori S; Papi M; Drudi F; Castellani C; Carloni F; Tombesi P; Lazzari-Agli L
    Oncology; 2011; 80(5-6):350-8. PubMed ID: 21791945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
    Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
    Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.
    Nuijten MJ; Aultman R; Carpeño Jde C; Vergnenègre A; Chouaid C; Walzer S; Siebert U
    Curr Med Res Opin; 2011 Nov; 27(11):2193-201. PubMed ID: 21970659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New antiangiogenetic agents and non-small cell lung cancer.
    Gridelli C; Rossi A; Maione P
    Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of bevacizumab for the treatment of non-small-cell lung cancer.
    Ramalingam S; Belani CP
    Future Oncol; 2007 Apr; 3(2):131-9. PubMed ID: 17381412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.